EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The impact of artificial intelligence on biomarker discovery

Hira Javaid, Constantin Cezar Petrescu iD, Lisa J Schmunk iD, Jack M Monahan iD, Paul O'Reilly, Manik Garg iD, Leona McGirr, Mahmoud T Khasawneh, Mustafa Al Lail, Deepak Ganta iD, Thomas M Stubbs iD, Benjamin B Sun iD und 2 weitere

Emerging Topics in Life Sciences · 11.09.2025 · 8 (2) · 89-105

DOI: 10.1042/etls20243003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Emerging Topics in Life Sciences, online erschienen am 09.09.2025. Verfasst von Hira Javaid und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hurdle.bio / Chronomics Ltd., London, UK. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artificial intelligence (AI) is transforming many fields, including healthcare and medicine. In biomarker discovery, AI algorithms have had a profound impact, thanks to their ability to derive insights from complex high-dimensional datasets and integrate multi-modal datatypes (such as omics, electronic health records, imaging or sensor and wearable data). However, despite the proliferation of AI-powered biomarkers, significant hurdles still remain in translating them to the clinic and driving adoption, including lack of population diversity, difficulties accessing harmonised data, costly and time-consuming clinical studies, evolving AI regulatory frameworks and absence of scalable diagnostic infrastructure. Here, we provide an overview of the AI toolkit available for biomarker discovery, and we discuss exciting examples of AI-powered biomarkers across therapeutic areas. Finally, we address the challenges ahead of us to ensure that these technologies reach patients and users globally and unlock a new era of fast innovation for precision medicine.

Schlagwörter

Stichwörter der Autor:innen

artificial intelligencebiomarker discoverybiomarkersdiagnosticselectronic health recordsmulti-modal datamulti-omics

Autor:innen und Institutionen

  • Hurdle.bio / Chronomics Ltd., London, UK.
  • Biomodal Ltd, The Trinity Building, Chesterford Business Park, Cambridge, UK.
  • Sonrai Analytics Ltd, Queens Road, Belfast, Northern Ireland, UK.
  • Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Texas A&M International University, Laredo, Texas, U.S.A.
  • Bristol Myers Squibb, New York, U.S.A.

ORCID-Profile: Constantin Cezar Petrescu, Lisa J Schmunk, Jack M Monahan, Manik Garg, Deepak Ganta, Thomas M Stubbs, Benjamin B Sun, Dimitrios Vitsios, Daniel E Martin-Herranz

Zitieren

APA

Javaid, H., Petrescu, C. C., Schmunk, L. J., Monahan, J. M., O'Reilly, P., Garg, M., McGirr, L., Khasawneh, M. T., Al Lail, M., Ganta, D., Stubbs, T. M., Sun, B. B., Vitsios, D., & Martin-Herranz, D. E. (2025). The impact of artificial intelligence on biomarker discovery. Emerging Topics in Life Sciences, 8(2), 89-105. https://doi.org/10.1042/etls20243003

Vancouver

Javaid H, Petrescu CC, Schmunk LJ, Monahan JM, O'Reilly P, Garg M, et al. The impact of artificial intelligence on biomarker discovery. Emerging Topics in Life Sciences. 2025;8(2):89-105. doi:10.1042/etls20243003

BibTeX
@article{Javaid2025,
  author = {Javaid, Hira and Petrescu, Constantin Cezar and Schmunk, Lisa J and Monahan, Jack M and O'Reilly, Paul and Garg, Manik and McGirr, Leona and Khasawneh, Mahmoud T and Al Lail, Mustafa and Ganta, Deepak and Stubbs, Thomas M and Sun, Benjamin B and Vitsios, Dimitrios and Martin-Herranz, Daniel E},
  title = {The impact of artificial intelligence on biomarker discovery},
  journal = {Emerging Topics in Life Sciences},
  year = {2025},
  volume = {8},
  number = {2},
  pages = {89--105},
  doi = {10.1042/etls20243003}
}
Kostenlos starten →